ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)

Market Cap	52.18M +5.3%
Revenue (ttm)	10.85M +36.8%
Net Income	-45.17M
EPS	-17.71
Shares Out	3.53M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,158
Average Volume	15,993
Open	16.50
Previous Close	16.60
Day's Range	14.24 - 16.52
52-Week Range	14.00 - 34.20
Beta	2.43
RSI	44.79
Earnings Date	Feb 19, 2026

About STO:EXPRS2

ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalovirus vaccine program to treat infectious diseases, as well as vaccines for Nipah virus, Malaria, and influenza. In addition, the company offers a huma...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 20
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EXPRS2

Financial Performance

In 2024, STO:EXPRS2's revenue was 7.83 million, a decrease of -11.07% compared to the previous year's 8.80 million. Losses were -36.04 million, -60.57% less than in 2023.